KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT03848286 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma
Recurrent or Metastatic

Interventions

DRUG: KL-A167 Injection

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.